Stephen-Haynes J, Callaghan R, Wibaux A, Johnson P, Carty N
Professional Development Unit, Birmingham City University.
J Wound Care. 2014 Nov;23(11):532, 534, 536 passim. doi: 10.12968/jowc.2014.23.11.532.
This article assesses the use of BeneHold Thin Absorbent Skin Adhesive (TASA) wound dressings in a large UK primary care organisation. These wound dressings are thin (0.12 mm), breathable, transparent, and are able to absorb and retain wound exudate. This non-comparative evaluation was undertaken to explore the clinical advantages this differentiated combination of physical properties offered.
The dressings are CE-marked medical devices, and were used on patients with acute and chronic wounds that were assessed and classified as light to moderately exuding. Clinical performance was evaluated with respect to the dressing's ease of use (application and removal, conformability, mould-ability, rolling and edge-lift), debridement, protection of the peri-wound, wear time, fluid handling, wound bed residue, visibility of the wound, and clinical acceptability. The evaluating clinicians used an agreed audit tool to collect data from case reports to document the progression of wounds of various aetiologies, including chronic and acute, for a maximum period of four weeks. Qualitative feedback on dressing performance was also collected at the evaluation's end, both from the clinicians' and patients' perspectives Results: Some 15 patients were assessed. The wear time was up to seven days in many cases, and on average was 3.9 days longer than their previous dressings. Clinicians perceived that wounds progressed toward healing in all but two cases, where the wounds remained unchanged. Out of five cases where wounds presented with necrosis, all underwent significant autolytic debridement underneath the new dressings. Transparency was a noted benefit from both the clinicians' and patients' perspectives because it enabled continuous monitoring of the full wound bed and peri-wound skin without the need to disrupt the dressing.
The dressing was well-received by both clinicians and patients in all fifteen cases. The thin absorbent skin adhesive dressing was found to be a promising new technology that could offer significant advantages to improve the quality, cost, and convenience of wound care. Further work is underway to validate these findings in larger and more homogeneous patient groups.
本文评估了BeneHold薄型吸收性皮肤粘合剂（TASA）伤口敷料在英国一家大型初级医疗保健机构中的使用情况。这些伤口敷料很薄（0.12毫米），透气、透明，能够吸收并保留伤口渗出液。进行这项非对照评估是为了探究这种独特物理特性组合所带来的临床优势。
这些敷料是带有CE标志的医疗器械，用于患有急性和慢性伤口且经评估和分类为轻度至中度渗出的患者。从敷料的易用性（粘贴和去除、贴合性、塑形性、卷边和边缘翘起情况）、清创、伤口周围保护、佩戴时间、液体处理、伤口床残留物、伤口可视性以及临床可接受性等方面对临床性能进行了评估。评估临床医生使用商定的审核工具从病例报告中收集数据，以记录各种病因（包括慢性和急性）伤口长达四周的愈合进展情况。在评估结束时，还从临床医生和患者的角度收集了关于敷料性能的定性反馈。
共评估了约15名患者。在许多情况下，佩戴时间长达七天，平均比之前使用的敷料长3.9天。临床医生认为，除两例伤口无变化外，其他所有伤口均朝着愈合方向发展。在五例出现坏死的伤口中，所有伤口在新敷料下均经历了显著的自溶性清创。从临床医生和患者的角度来看，透明度都是一个显著优点，因为它能够在不干扰敷料的情况下持续监测整个伤口床和伤口周围皮肤。
在所有15个病例中，该敷料均受到临床医生和患者的好评。这种薄型吸收性皮肤粘合剂敷料被认为是一项有前景的新技术，可为改善伤口护理的质量、成本和便利性带来显著优势。目前正在开展进一步工作，以在更大且更同质的患者群体中验证这些发现。
